J&J depression drug aces trial, Takeda plans layoffs, FDA delays review of Sanofi-Regeneron's Dupixent [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — J&J depression drug aces late-stage trial
The bad — Takeda plans layoffs at Massachusetts sites
The ugly — FDA delays review of Sanofi-Regeneron's Dupixent in COPD